Trial reportJournal of neuro-oncology2004
Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.
Trial report in Journal of neuro-oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 95 citations in OpenAlex.
- Modulation of Drug Resistance and Apoptotic Pathways Underlies the Enhanced Antitumor Effect of Ellagic Acid-Irinotecan Combination in Glioma.International journal of molecular sciences · 2026Article
- Association Between MGMT Promoter Methylation and Clinical and Lifestyle Factors in Glioblastoma: A Single-Center Study in Korea.Journal of clinical medicine · 2026Article
- Modulating microenvironments for treating glioblastoma.Current tissue microenvironment reports · 2020Article
- Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma.Oncotarget · 2018Article
- Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide).Scientific reports · 2018Article
- Treatment of glioblastoma with herbal medicines.World journal of surgical oncology · 2018Article
- MicroRNA-142-3p is involved in regulation ofCancer management and research · 2018Article
- TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.African journal of traditional, complementary, and alternative medicines : AJTCAM · 2016Article
- Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).International journal of oncology · 2015Review
- DNA methylation biomarkers: cancer and beyond.Genes · 2014Review
- Drug resistance in cancer: an overview.Cancers · 2014Review
- The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.Molecular cancer therapeutics · 2014Article
- MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy.Journal of translational medicine · 2012Article
- Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.Medical oncology (Northwood, London, England) · 2012Article
- Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging.Neuroradiology · 2012Article
- MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR.Journal of translational medicine · 2012Article
- O⁶-methylguanine-DNA-methyltransferase promoter methylation assessment by microdissection-assisted methylation-specific PCR and high resolution melting analysis in patients with glioblastomas.Journal of neuro-oncology · 2012Article
- O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.International journal of molecular sciences · 2012Article
- MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.Cancer science · 2011Article
- Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas.Journal of neuro-oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In an effort to extend the potential relationship between the methylation status of MGMT promoter and response to CENU therapy, we examined the methylation status of MGMT promoter in 44 patients with glioblastomas. Tumor specimens were obtained during surgery before adjuvant treatment, frozen and stored at -80 degrees C until for DNA extraction process. DNA methylation patterns in the CpG island of the MGMT gene were determined in every tumor by methylation specific PCR (MSP). These results were then related to overall survival and response to alkylating agents using statistical analysis. Methylation of the MGMT promoter was detected in 68% of tumors, and 96.7% of methylated tumors exhibited also an unmethylated status. There was no relationship between the methylation status of the MGMT promoter and overall survival and response to alkylating agents. Our observations do not lead us to consider promoter methylation of MGMT gene as a prognostic factor of responsiveness to alkylating agents in glioblastomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.